JP2007509106A5 - - Google Patents

Download PDF

Info

Publication number
JP2007509106A5
JP2007509106A5 JP2006536068A JP2006536068A JP2007509106A5 JP 2007509106 A5 JP2007509106 A5 JP 2007509106A5 JP 2006536068 A JP2006536068 A JP 2006536068A JP 2006536068 A JP2006536068 A JP 2006536068A JP 2007509106 A5 JP2007509106 A5 JP 2007509106A5
Authority
JP
Japan
Prior art keywords
methyl
amino
pyridinyl
pyrimidinyl
benzamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006536068A
Other languages
English (en)
Japanese (ja)
Other versions
JP4827737B2 (ja
JP2007509106A (ja
Filing date
Publication date
Priority claimed from GBGB0325031.3A external-priority patent/GB0325031D0/en
Application filed filed Critical
Publication of JP2007509106A publication Critical patent/JP2007509106A/ja
Publication of JP2007509106A5 publication Critical patent/JP2007509106A5/ja
Application granted granted Critical
Publication of JP4827737B2 publication Critical patent/JP4827737B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2006536068A 2003-10-27 2004-10-26 アミロイド関連疾患の処置のためのピリジニル−ピリミジニルアミノ−ベンズアミド誘導体の使用 Expired - Fee Related JP4827737B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0325031.3A GB0325031D0 (en) 2003-10-27 2003-10-27 Organic compounds
GB0325031.3 2003-10-27
PCT/EP2004/012080 WO2005039586A1 (en) 2003-10-27 2004-10-26 Use of pyridinyl-pyrimidinylamino-benzamide derivatives for the treatment of amyloid related disorders

Publications (3)

Publication Number Publication Date
JP2007509106A JP2007509106A (ja) 2007-04-12
JP2007509106A5 true JP2007509106A5 (cg-RX-API-DMAC7.html) 2007-12-13
JP4827737B2 JP4827737B2 (ja) 2011-11-30

Family

ID=29725439

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006536068A Expired - Fee Related JP4827737B2 (ja) 2003-10-27 2004-10-26 アミロイド関連疾患の処置のためのピリジニル−ピリミジニルアミノ−ベンズアミド誘導体の使用

Country Status (4)

Country Link
US (1) US7687512B2 (cg-RX-API-DMAC7.html)
JP (1) JP4827737B2 (cg-RX-API-DMAC7.html)
GB (1) GB0325031D0 (cg-RX-API-DMAC7.html)
WO (1) WO2005039586A1 (cg-RX-API-DMAC7.html)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006083477A2 (en) 2005-01-07 2006-08-10 Synta Pharmaceuticals Corp. Compounds for inflammation and immune-related uses
MX2007009135A (es) * 2005-01-28 2007-09-06 Novartis Ag Uso de pirimidilaminobenzamidas para el tratamiento de enfermedades que responden a la modulacion de la actividad de la cinasa tie-2.
KR101519311B1 (ko) 2005-05-02 2015-05-11 노파르티스 아게 과호산구성 증후군을 위한 피리미딜아미노벤즈아미드 유도체
GT200600315A (es) * 2005-07-20 2007-03-19 Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida
CA2629132C (en) 2005-12-06 2014-05-27 Novartis Ag Pyrimidylaminobenzamide derivatives for the treatment of neurofibromatosis
US20100048713A1 (en) * 2006-01-06 2010-02-25 Aarhus Universitet Compounds acting on the serotonin transporter
CA2660836A1 (en) 2006-08-07 2008-02-21 Incyte Corporation Triazolotriazines as kinase inhibitors
EP1923053A1 (en) 2006-09-27 2008-05-21 Novartis AG Pharmaceutical compositions comprising nilotinib or its salt
AU2007320906A1 (en) 2006-11-13 2008-05-22 Pfizer Products Inc. Diaryl, dipyridinyl and aryl-pyridinyl derivatives and uses thereof
AU2007323725B2 (en) 2006-11-22 2014-02-20 Incyte Holdings Corporation Imidazotriazines and imidazopyrimidines as kinase inhibitors
FR2913886B1 (fr) 2007-03-22 2012-03-02 Guerbet Sa Utilisation de nanoparticules metalliques dans le diagnostique de la maladie d'alzheimer
US8242271B2 (en) * 2007-06-04 2012-08-14 Avila Therapeutics, Inc. Heterocyclic compounds and uses thereof
EP2166860B1 (en) 2007-06-07 2016-09-21 Intra-Cellular Therapies, Inc. Novel heterocycle compounds and uses thereof
US8367686B2 (en) 2007-06-07 2013-02-05 Intra-Cellular Therapies, Inc. Heterocycle compounds and uses thereof
WO2009036066A1 (en) * 2007-09-10 2009-03-19 Curis, Inc. Vegfr inhibitors containing a zinc binding moiety
MX393622B (es) 2008-05-21 2025-03-24 Incyte Corp Sales de 2-fluoro-n-metil-4-[7-(quinolin-6-il-metil)-imidazo[1,2-b][1,2,4]triazin-2-il]benzamida y procesos relacionados con la preparacion de las mismas.
CA2729012A1 (en) 2008-06-27 2009-12-30 Amgen Inc. Ang-2 inhibition to treat multiple sclerosis
EP2315592A1 (en) * 2008-08-13 2011-05-04 Novartis AG Treatment of pulmonary arterial hypertension
WO2010036813A1 (en) * 2008-09-24 2010-04-01 University Of South Florida Materials and methods for preventing or treating neurodegenerative conditions associated with abeta peptide accumulation
KR20110075016A (ko) 2008-10-14 2011-07-05 닝 시 화합물 및 사용 방법
EP2530081A3 (en) 2008-11-05 2013-04-10 Teva Pharmaceutical Industries, Ltd. Nilotinib HCI crystalline forms
WO2010060074A1 (en) * 2008-11-24 2010-05-27 Teva Pharmaceutical Industries Ltd. Preparation of nilotinib and intermediates thereof
CN102316738A (zh) * 2009-02-18 2012-01-11 盛泰萨路申有限公司 作为激酶抑制剂的酰胺类
EP2408300B1 (en) * 2009-03-21 2016-05-11 Sunshine Lake Pharma Co., Ltd. Amino ester derivatives, salts thereof and methods of use
SG10201507362TA (en) 2009-08-05 2015-10-29 Intra Cellular Therapies Inc Novel Regulatory Proteins And Inhibitors
BR112012007137A2 (pt) 2009-09-30 2015-09-15 Harvard College metodos para modulacao da autofagia por meio da modulacao de produtos genicos inibidores da autofagia
EP2531509B1 (en) 2010-02-03 2016-10-05 Incyte Holdings Corporation Imidazo[1,2-b][1,2,4]triazines as c-met inhibitors
EP2554163A4 (en) * 2010-03-26 2013-07-17 Univ Hokkaido Nat Univ Corp THERAPEUTIC ACTIVE FOR NEURODEGENERATIVE DISEASES
KR101924247B1 (ko) 2011-07-27 2019-02-22 에이비 사이언스 선택적 프로테인 키나제 저해제로서 옥사졸 및 티아졸 유도체
AU2013256227B2 (en) 2012-05-02 2017-06-15 Georgetown University Treating neural disease with tyrosine kinase inhibitors
MY179781A (en) * 2013-12-11 2020-11-13 Biogen Ma Inc Biaryl inhibitors of bruton's tyrosine kinase
JP6668329B2 (ja) 2015-03-25 2020-03-18 国立研究開発法人国立長寿医療研究センター 新規オキサジアゾール誘導体及びこれを含有する医薬
CN105030776A (zh) * 2015-06-24 2015-11-11 北京键凯科技有限公司 Src蛋白抑制剂在制备预防和/治疗阿尔兹海默病药物中的应用
CN106905298A (zh) * 2015-12-22 2017-06-30 江苏先声药业有限公司 盐酸尼洛替尼杂质的制备方法
WO2018148533A1 (en) 2017-02-09 2018-08-16 Georgetown University Compositions and methods for treating lysosomal storage disorders
US12290516B2 (en) * 2017-05-12 2025-05-06 The Hong Kong University Of Science And Technology Heterocyclic compounds as EphA4 inhibitors
WO2020056132A1 (en) * 2018-09-13 2020-03-19 University Of Southern California Novel fgfr inhibitors and uses thereof
AU2019385480B2 (en) 2018-11-20 2025-04-24 Georgetown University Compositions and methods for treating neurodegenerative, myodegenerative, and lysosomal storage disorders
EP3935057A4 (en) * 2019-03-05 2023-03-01 Hongyi & Associates LLC Compounds for treating neurodegenerative diseases and cancers

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5516775A (en) * 1992-08-31 1996-05-14 Ciba-Geigy Corporation Further use of pyrimidine derivatives
ATE208772T1 (de) 1993-10-01 2001-11-15 Novartis Erfind Verwalt Gmbh Pharmacologisch wirksame pyridinderivate und verfahren zu deren herstellung
EP1401831A1 (en) * 2001-07-03 2004-03-31 Chiron Corporation Indazole benzimidazole compounds as tyrosine and serine/threonine kinase inhibitors
WO2003057165A2 (en) * 2002-01-04 2003-07-17 The Rockefeller University COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF AMYLOID-β PEPTIDE-RELATED DISORDERS
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
GB0222514D0 (en) * 2002-09-27 2002-11-06 Novartis Ag Organic compounds

Similar Documents

Publication Publication Date Title
JP2007509106A5 (cg-RX-API-DMAC7.html)
JP4827737B2 (ja) アミロイド関連疾患の処置のためのピリジニル−ピリミジニルアミノ−ベンズアミド誘導体の使用
CN1960731B (zh) 调节炎性和转移过程的方法
AU2001248324B2 (en) Use of pdgf receptor tyrosine kinase inhibitors for the treatment of diabetic nephropathy
RU2008135690A (ru) Соединения и композиции в качестве ингибиторов протеинкиназы
AU2016216636B2 (en) Method of treating proliferative disorders and other pathological conditions mediated by Bcr-Abl, c-Kit, DDR1, DDR2 or PDGF-R kinase activity
JP2011530607A5 (cg-RX-API-DMAC7.html)
WO2009017455A1 (en) A new combination of (a) an alpha-4-beta-2 -neuronal nicotinic agonist and (b) a gsk3 inhibitor
JP2008513514A5 (cg-RX-API-DMAC7.html)
JP2014098044A (ja) 腎機能障害の治療用の医薬の製造のためのドーパミン−ｄ３−レセプターリガンドの使用
JP7398831B2 (ja) 神経変性疾患の予防及び／又は治療剤
RU2017121044A (ru) Производные амидотиадиазола в качестве ингибиторов надфн-оксидазы
JP2009542638A5 (cg-RX-API-DMAC7.html)
JP2007523181A5 (cg-RX-API-DMAC7.html)
JP2009532438A5 (cg-RX-API-DMAC7.html)
RU2304436C2 (ru) Применение производных n-фенил-2-пиримидинамина против основывающихся на мастоцитах заболеваний, подобных аллергическим нарушениям
AU2020229558A1 (en) Combinational medication
RU2011105059A (ru) Применение производных пиримидиламинобензамида для лечения фиброза
TWI565466B (zh) 由α－碳酸酐酶之異形體調節之哺乳動物之疾病之治療
JP2009537606A5 (cg-RX-API-DMAC7.html)
RU2008127264A (ru) Производные пиримидиламинобензамида, предназначенные для лечения нейрофиброматоза
BRPI0710496A2 (pt) combinação que compreende a) composto de pirimidilaminobenzamida e b) inibidor de thr315iie cinase
JP2012519668A5 (cg-RX-API-DMAC7.html)
JP5936821B2 (ja) チロシンキナーゼ型受容体ｋｉｔによって媒介される増殖性疾患のイマチニブによる処置を最適化する方法
AU2011202833B2 (en) Combination comprising a) a pyrimidylaminobenzamide compound, and b) a Thr315lle kinase inhibitor